Limited subtotal gastrectomy for early remnant gastric cancer
Background Detection of early remnant gastric cancer (ERGC) is increasing as a result of the development of endoscopic technology and a surveillance program. The aim of this study was to evaluate the results of limited subtotal gastrectomy (SG) surgery for ERGC compared to total gastrectomy (TG). Me...
Gespeichert in:
| Veröffentlicht in: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2014-04, Vol.17 (2), p.332-336 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 336 |
|---|---|
| container_issue | 2 |
| container_start_page | 332 |
| container_title | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |
| container_volume | 17 |
| creator | Hosokawa, Yuichi Konishi, Masaru Sahara, Yatsuka Kinoshita, Takahiro Takahashi, Shinichiro Gotohda, Naoto Kato, Yuichiro Kinoshita, Taira |
| description | Background
Detection of early remnant gastric cancer (ERGC) is increasing as a result of the development of endoscopic technology and a surveillance program. The aim of this study was to evaluate the results of limited subtotal gastrectomy (SG) surgery for ERGC compared to total gastrectomy (TG).
Methods
We retrospectively reviewed a database of 72 consecutive patients with remnant gastric cancer who underwent laparotomy at the National Cancer Center Hospital East between January 1993 and December 2008. Thirty-five patients with a preoperative diagnosis of ERGC underwent curative resection: 13 SG and 22 conventional TG. Patients and tumor characteristics, operative results, and postoperative assessments 1 year after surgery were compared between the two groups.
Results
Operating time, blood transfusion, and hospital stay were similar in the two groups. In the SG group, blood loss and postoperative recovery of body weight tended to be better than in the TG group. There was no dumping syndrome in the SG group, while this occurred in three patients in the TG group. The levels of hemoglobin and total protein were higher 1 year after remnant gastrectomy in the SG group than in the TG group. No recurrence of gastric cancer was detected in the SG group during median follow-up of 99.2 months.
Conclusion
In comparison to TG, limited SG surgery for ERGC improved the postoperative course, with no recurrence of cancer. Therefore, SG is a safe and effective treatment for ERGC. |
| doi_str_mv | 10.1007/s10120-013-0280-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1513045969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1513045969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-acb454b268f54c18248c42954f83865313a7aab6c66b00e8176c9df5cf92ca73</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMoVqs_wIssePGyOpOvzR48SPELCl56D9k0W1b2Q5Psof_elG1FBC-ZwDzzzvAQcoVwhwDFfUBACjkgy4EqyNUROUPOZM4YiOPDn5Y4I-chfACgKFGekhllitH0nJGHZdM10a2zMFZxiKbNNiZE72wcum1WDz5zxrfbzLuuN32cuo3NrOmt8xfkpDZtcJf7Oier56fV4jVfvr-8LR6XueVSxtzYigteUalqwS0qypXltBS8VkxJwZCZwphKWikrAKewkLZc18LWJbWmYHNyO8V--uFrdCHqrgnWta3p3TAGjQIZcFHKMqE3f9CPYfR9Om5HUVRSFTJROFHWDyF4V-tP33TGbzWC3qnVk1qd1OqdWq3SzPU-eaw6t_6ZOLhMAJ2AkFr9xvlfq_9N_QZiboI8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1512186876</pqid></control><display><type>article</type><title>Limited subtotal gastrectomy for early remnant gastric cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hosokawa, Yuichi ; Konishi, Masaru ; Sahara, Yatsuka ; Kinoshita, Takahiro ; Takahashi, Shinichiro ; Gotohda, Naoto ; Kato, Yuichiro ; Kinoshita, Taira</creator><creatorcontrib>Hosokawa, Yuichi ; Konishi, Masaru ; Sahara, Yatsuka ; Kinoshita, Takahiro ; Takahashi, Shinichiro ; Gotohda, Naoto ; Kato, Yuichiro ; Kinoshita, Taira</creatorcontrib><description>Background
Detection of early remnant gastric cancer (ERGC) is increasing as a result of the development of endoscopic technology and a surveillance program. The aim of this study was to evaluate the results of limited subtotal gastrectomy (SG) surgery for ERGC compared to total gastrectomy (TG).
Methods
We retrospectively reviewed a database of 72 consecutive patients with remnant gastric cancer who underwent laparotomy at the National Cancer Center Hospital East between January 1993 and December 2008. Thirty-five patients with a preoperative diagnosis of ERGC underwent curative resection: 13 SG and 22 conventional TG. Patients and tumor characteristics, operative results, and postoperative assessments 1 year after surgery were compared between the two groups.
Results
Operating time, blood transfusion, and hospital stay were similar in the two groups. In the SG group, blood loss and postoperative recovery of body weight tended to be better than in the TG group. There was no dumping syndrome in the SG group, while this occurred in three patients in the TG group. The levels of hemoglobin and total protein were higher 1 year after remnant gastrectomy in the SG group than in the TG group. No recurrence of gastric cancer was detected in the SG group during median follow-up of 99.2 months.
Conclusion
In comparison to TG, limited SG surgery for ERGC improved the postoperative course, with no recurrence of cancer. Therefore, SG is a safe and effective treatment for ERGC.</description><identifier>ISSN: 1436-3291</identifier><identifier>EISSN: 1436-3305</identifier><identifier>DOI: 10.1007/s10120-013-0280-8</identifier><identifier>PMID: 23832238</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Abdominal Surgery ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer Research ; Case-Control Studies ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Gastric cancer ; Gastroenterology ; Humans ; Lymphatic Metastasis ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Neoplasms - drug therapy ; Neoplasms - pathology ; Oncology ; Original Article ; Prognosis ; Retrospective Studies ; Surgical Oncology ; Survival Rate</subject><ispartof>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014-04, Vol.17 (2), p.332-336</ispartof><rights>The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2013</rights><rights>The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-acb454b268f54c18248c42954f83865313a7aab6c66b00e8176c9df5cf92ca73</citedby><cites>FETCH-LOGICAL-c466t-acb454b268f54c18248c42954f83865313a7aab6c66b00e8176c9df5cf92ca73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10120-013-0280-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10120-013-0280-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23832238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hosokawa, Yuichi</creatorcontrib><creatorcontrib>Konishi, Masaru</creatorcontrib><creatorcontrib>Sahara, Yatsuka</creatorcontrib><creatorcontrib>Kinoshita, Takahiro</creatorcontrib><creatorcontrib>Takahashi, Shinichiro</creatorcontrib><creatorcontrib>Gotohda, Naoto</creatorcontrib><creatorcontrib>Kato, Yuichiro</creatorcontrib><creatorcontrib>Kinoshita, Taira</creatorcontrib><title>Limited subtotal gastrectomy for early remnant gastric cancer</title><title>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</title><addtitle>Gastric Cancer</addtitle><addtitle>Gastric Cancer</addtitle><description>Background
Detection of early remnant gastric cancer (ERGC) is increasing as a result of the development of endoscopic technology and a surveillance program. The aim of this study was to evaluate the results of limited subtotal gastrectomy (SG) surgery for ERGC compared to total gastrectomy (TG).
Methods
We retrospectively reviewed a database of 72 consecutive patients with remnant gastric cancer who underwent laparotomy at the National Cancer Center Hospital East between January 1993 and December 2008. Thirty-five patients with a preoperative diagnosis of ERGC underwent curative resection: 13 SG and 22 conventional TG. Patients and tumor characteristics, operative results, and postoperative assessments 1 year after surgery were compared between the two groups.
Results
Operating time, blood transfusion, and hospital stay were similar in the two groups. In the SG group, blood loss and postoperative recovery of body weight tended to be better than in the TG group. There was no dumping syndrome in the SG group, while this occurred in three patients in the TG group. The levels of hemoglobin and total protein were higher 1 year after remnant gastrectomy in the SG group than in the TG group. No recurrence of gastric cancer was detected in the SG group during median follow-up of 99.2 months.
Conclusion
In comparison to TG, limited SG surgery for ERGC improved the postoperative course, with no recurrence of cancer. Therefore, SG is a safe and effective treatment for ERGC.</description><subject>Abdominal Surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><issn>1436-3291</issn><issn>1436-3305</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1LAzEQhoMoVqs_wIssePGyOpOvzR48SPELCl56D9k0W1b2Q5Psof_elG1FBC-ZwDzzzvAQcoVwhwDFfUBACjkgy4EqyNUROUPOZM4YiOPDn5Y4I-chfACgKFGekhllitH0nJGHZdM10a2zMFZxiKbNNiZE72wcum1WDz5zxrfbzLuuN32cuo3NrOmt8xfkpDZtcJf7Oier56fV4jVfvr-8LR6XueVSxtzYigteUalqwS0qypXltBS8VkxJwZCZwphKWikrAKewkLZc18LWJbWmYHNyO8V--uFrdCHqrgnWta3p3TAGjQIZcFHKMqE3f9CPYfR9Om5HUVRSFTJROFHWDyF4V-tP33TGbzWC3qnVk1qd1OqdWq3SzPU-eaw6t_6ZOLhMAJ2AkFr9xvlfq_9N_QZiboI8</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Hosokawa, Yuichi</creator><creator>Konishi, Masaru</creator><creator>Sahara, Yatsuka</creator><creator>Kinoshita, Takahiro</creator><creator>Takahashi, Shinichiro</creator><creator>Gotohda, Naoto</creator><creator>Kato, Yuichiro</creator><creator>Kinoshita, Taira</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Limited subtotal gastrectomy for early remnant gastric cancer</title><author>Hosokawa, Yuichi ; Konishi, Masaru ; Sahara, Yatsuka ; Kinoshita, Takahiro ; Takahashi, Shinichiro ; Gotohda, Naoto ; Kato, Yuichiro ; Kinoshita, Taira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-acb454b268f54c18248c42954f83865313a7aab6c66b00e8176c9df5cf92ca73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Abdominal Surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hosokawa, Yuichi</creatorcontrib><creatorcontrib>Konishi, Masaru</creatorcontrib><creatorcontrib>Sahara, Yatsuka</creatorcontrib><creatorcontrib>Kinoshita, Takahiro</creatorcontrib><creatorcontrib>Takahashi, Shinichiro</creatorcontrib><creatorcontrib>Gotohda, Naoto</creatorcontrib><creatorcontrib>Kato, Yuichiro</creatorcontrib><creatorcontrib>Kinoshita, Taira</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hosokawa, Yuichi</au><au>Konishi, Masaru</au><au>Sahara, Yatsuka</au><au>Kinoshita, Takahiro</au><au>Takahashi, Shinichiro</au><au>Gotohda, Naoto</au><au>Kato, Yuichiro</au><au>Kinoshita, Taira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limited subtotal gastrectomy for early remnant gastric cancer</atitle><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle><stitle>Gastric Cancer</stitle><addtitle>Gastric Cancer</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>17</volume><issue>2</issue><spage>332</spage><epage>336</epage><pages>332-336</pages><issn>1436-3291</issn><eissn>1436-3305</eissn><abstract>Background
Detection of early remnant gastric cancer (ERGC) is increasing as a result of the development of endoscopic technology and a surveillance program. The aim of this study was to evaluate the results of limited subtotal gastrectomy (SG) surgery for ERGC compared to total gastrectomy (TG).
Methods
We retrospectively reviewed a database of 72 consecutive patients with remnant gastric cancer who underwent laparotomy at the National Cancer Center Hospital East between January 1993 and December 2008. Thirty-five patients with a preoperative diagnosis of ERGC underwent curative resection: 13 SG and 22 conventional TG. Patients and tumor characteristics, operative results, and postoperative assessments 1 year after surgery were compared between the two groups.
Results
Operating time, blood transfusion, and hospital stay were similar in the two groups. In the SG group, blood loss and postoperative recovery of body weight tended to be better than in the TG group. There was no dumping syndrome in the SG group, while this occurred in three patients in the TG group. The levels of hemoglobin and total protein were higher 1 year after remnant gastrectomy in the SG group than in the TG group. No recurrence of gastric cancer was detected in the SG group during median follow-up of 99.2 months.
Conclusion
In comparison to TG, limited SG surgery for ERGC improved the postoperative course, with no recurrence of cancer. Therefore, SG is a safe and effective treatment for ERGC.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>23832238</pmid><doi>10.1007/s10120-013-0280-8</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1436-3291 |
| ispartof | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014-04, Vol.17 (2), p.332-336 |
| issn | 1436-3291 1436-3305 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1513045969 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Abdominal Surgery Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Case-Control Studies Combined Modality Therapy Female Follow-Up Studies Gastric cancer Gastroenterology Humans Lymphatic Metastasis Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Staging Neoplasms - drug therapy Neoplasms - pathology Oncology Original Article Prognosis Retrospective Studies Surgical Oncology Survival Rate |
| title | Limited subtotal gastrectomy for early remnant gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T14%3A35%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limited%20subtotal%20gastrectomy%20for%20early%20remnant%20gastric%20cancer&rft.jtitle=Gastric%20cancer%20:%20official%20journal%20of%20the%20International%20Gastric%20Cancer%20Association%20and%20the%20Japanese%20Gastric%20Cancer%20Association&rft.au=Hosokawa,%20Yuichi&rft.date=2014-04-01&rft.volume=17&rft.issue=2&rft.spage=332&rft.epage=336&rft.pages=332-336&rft.issn=1436-3291&rft.eissn=1436-3305&rft_id=info:doi/10.1007/s10120-013-0280-8&rft_dat=%3Cproquest_cross%3E1513045969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1512186876&rft_id=info:pmid/23832238&rfr_iscdi=true |